(Q42946276)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Wen-Pyng Wu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Chi-Hao Chang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Yung-Tsung Chiu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mei-Chin Wen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Kuo-Hsiung Shu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ming-Ju Wu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

4 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Physiology - Renal Physiology

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

F929-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20685818%20AND%20SRC:MED&resulttype=core&format=json

Direct renin inhibition: clinical pharmacology

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

The role of tubulointerstitial injury in chronic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Review: renal protection by inhibition of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Direct renin inhibition: an analysis of possible benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Therapeutic potential of TGF-beta inhibition in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Effects of mycophenolate mofetil and lisinopril on collagen deposition in unilateral ureteral obstruction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Renin-angiotensin system blockade and cardiovascular and renal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Mast cells decrease renal fibrosis in unilateral ureteral obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Obstructive nephropathy and renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Direct renin inhibition with aliskiren in hypertension and target organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Macrophages and progressive tubulointerstitial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Now that we have a direct renin inhibitor, what should we do with it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Pathophysiology of unilateral ureteral obstruction: studies from Charlottesville to New York

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Effect of calbindin-D28K on cyclosporine toxicity in cultured renal proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010

Renal fibrosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00192.2010